Human monoclonal antibodies (MAbs) were selected from semisynthetic antibody phage display libraries by using whole irradiated severe acute respiratory syndrome (SARS) coronavirus (CoV) virions as target. We identified eight human MAbs binding to virus and infected cells, six of which could be mapped to two SARS-CoV structural proteins: the nucleocapsid (N) and spike (S) proteins. Two MAbs reacted with N protein. One of the N protein MAbs recognized a linear epitope conserved between all published human and animal SARS-CoV isolates, and the other bound to a nonlinear N epitope. These two N MAbs did not compete for binding to SARS-CoV. Four MAbs reacted with the S glycoprotein, and three of these MAbs neutralized SARS-CoV in vitro. All three neutralizing anti-S MAbs bound a recombinant S1 fragment comprising residues 318 to 510, a region previously identified as the SARS-CoV S receptor binding domain; the nonneutralizing MAb did not. Two strongly neutralizing anti-S1 MAbs blocked the binding of a recombinant S fragment (residues 1 to 565) to SARS-CoV-susceptible Vero cells completely, whereas a poorly neutralizing S1 MAb blocked binding only partially. The MAb ability to block S1-receptor binding and the level of neutralization ...Continue Reading
Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein
Coronavirus IBV: virus retaining spike glycopolypeptide S2 but not S1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protection
Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid
Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein
Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions
Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments
Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E
Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage
Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.
Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice
Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies
An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain
Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions.
Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV).
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants
The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.
Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain.
Selection and characterization of scFv antibodies against the Sin Nombre hantavirus nucleocapsid protein
The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine
Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses
Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness
Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.
The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries
Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine
Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention
Production of an anti-severe acute respiratory syndrome (SARS) coronavirus human monoclonal antibody Fab fragment by using a combinatorial immunoglobulin gene library derived from patients who recovered from SARS.
Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.
UBE2J2 promotes hepatocellular carcinoma cell epithelial-mesenchymal transition and invasion in vitro
SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes
Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics.
Antigenic modules in the N-terminal S1 region of the transmissible gastroenteritis virus spike protein
The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses
Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.